HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
NYSE:HAE - New York Stock Exchange, Inc. - US4050241003 - Common Stock - Currency: USD
Taking everything into account, HAE scores 5 out of 10 in our fundamental rating. HAE was compared to 187 industry peers in the Health Care Equipment & Supplies industry. HAE has an excellent profitability rating, but there are concerns on its financial health. HAE is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HAE was profitable.
HAE had a positive operating cash flow in the past year.
HAE had positive earnings in each of the past 5 years.
Each year in the past 5 years HAE had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HAE (6.84%) is better than 89.30% of its industry peers.
With an excellent Return On Equity value of 20.43%, HAE belongs to the best of the industry, outperforming 93.05% of the companies in the same industry.
HAE's Return On Invested Capital of 9.84% is amongst the best of the industry. HAE outperforms 91.98% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HAE is in line with the industry average of 7.89%.
The 3 year average ROIC (8.96%) for HAE is below the current ROIC(9.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.84% | ||
| ROE | 20.43% | ||
| ROIC | 9.84% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
The Profit Margin of HAE (12.32%) is better than 90.37% of its industry peers.
HAE's Profit Margin has improved in the last couple of years.
HAE's Operating Margin of 17.31% is amongst the best of the industry. HAE outperforms 88.24% of its industry peers.
In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
HAE has a Gross Margin of 55.87%. This is comparable to the rest of the industry: HAE outperforms 52.94% of its industry peers.
HAE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.31% | ||
| PM (TTM) | 12.32% | ||
| GM | 55.87% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HAE is creating some value.
HAE has less shares outstanding than it did 1 year ago.
HAE has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HAE has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.57 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
HAE's Altman-Z score of 2.57 is fine compared to the rest of the industry. HAE outperforms 63.64% of its industry peers.
The Debt to FCF ratio of HAE is 10.09, which is on the high side as it means it would take HAE, 10.09 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 10.09, HAE is doing good in the industry, outperforming 75.40% of the companies in the same industry.
HAE has a Debt/Equity ratio of 1.12. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of HAE (1.12) is worse than 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.12 | ||
| Debt/FCF | 10.09 | ||
| Altman-Z | 2.57 |
ROIC/WACC1.29
WACC7.61%
2.3 Liquidity
A Current Ratio of 1.62 indicates that HAE should not have too much problems paying its short term obligations.
HAE has a worse Current ratio (1.62) than 73.80% of its industry peers.
HAE has a Quick Ratio of 1.62. This is a bad value and indicates that HAE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.99, HAE is doing worse than 77.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.82% over the past year.
Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
The Revenue has been growing slightly by 3.96% in the past year.
The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)14.82%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%37.78%
Revenue 1Y (TTM)3.96%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-3.7%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.70% on average per year.
Based on estimates for the next years, HAE will show a small growth in Revenue. The Revenue will grow by 4.48% on average per year.
EPS Next Y7.64%
EPS Next 2Y11.63%
EPS Next 3Y11.7%
EPS Next 5YN/A
Revenue Next Year-3.57%
Revenue Next 2Y1.66%
Revenue Next 3Y4.48%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.72, which indicates a correct valuation of HAE.
82.89% of the companies in the same industry are more expensive than HAE, based on the Price/Earnings ratio.
HAE's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.15.
Based on the Price/Forward Earnings ratio of 15.53, the valuation of HAE can be described as correct.
84.49% of the companies in the same industry are more expensive than HAE, based on the Price/Forward Earnings ratio.
HAE's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.60.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.72 | ||
| Fwd PE | 15.53 |
4.2 Price Multiples
83.96% of the companies in the same industry are more expensive than HAE, based on the Enterprise Value to EBITDA ratio.
83.42% of the companies in the same industry are more expensive than HAE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.25 | ||
| EV/EBITDA | 12.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HAE does not grow enough to justify the current Price/Earnings ratio.
HAE has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.19
PEG (5Y)2.51
EPS Next 2Y11.63%
EPS Next 3Y11.7%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:HAE (7/1/2025, 3:24:57 PM)
76.405
+1.8 (+2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners118.39%
Inst Owner Change-6.32%
Ins Owners1.14%
Ins Owner Change7.49%
Market Cap3.67B
Analysts80
Price Target93.61 (22.52%)
Short Float %8.54%
Short Ratio7.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.66%
Min EPS beat(2)0.62%
Max EPS beat(2)0.69%
EPS beat(4)4
Avg EPS beat(4)1.28%
Min EPS beat(4)0.44%
Max EPS beat(4)3.35%
EPS beat(8)7
Avg EPS beat(8)8.39%
EPS beat(12)11
Avg EPS beat(12)9.55%
EPS beat(16)14
Avg EPS beat(16)8.94%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-2.22%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)-0.16%
Revenue beat(8)4
Avg Revenue beat(8)1.17%
Revenue beat(12)8
Avg Revenue beat(12)2.29%
Revenue beat(16)10
Avg Revenue beat(16)1.73%
PT rev (1m)-1.84%
PT rev (3m)-4.95%
EPS NQ rev (1m)-0.74%
EPS NQ rev (3m)-6.84%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-1.93%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)-4.35%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-2.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.72 | ||
| Fwd PE | 15.53 | ||
| P/S | 2.7 | ||
| P/FCF | 30.25 | ||
| P/OCF | 20.2 | ||
| P/B | 4.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.82 |
EPS(TTM)4.57
EY5.98%
EPS(NY)4.92
Fwd EY6.44%
FCF(TTM)2.53
FCFY3.31%
OCF(TTM)3.78
OCFY4.95%
SpS28.33
BVpS17.09
TBVpS-4.98
PEG (NY)2.19
PEG (5Y)2.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.84% | ||
| ROE | 20.43% | ||
| ROCE | 12.58% | ||
| ROIC | 9.84% | ||
| ROICexc | 11.77% | ||
| ROICexgc | 36.43% | ||
| OM | 17.31% | ||
| PM (TTM) | 12.32% | ||
| GM | 55.87% | ||
| FCFM | 8.92% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexcg growth 3Y22.36%
ROICexcg growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score6
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.12 | ||
| Debt/FCF | 10.09 | ||
| Debt/EBITDA | 2.62 | ||
| Cap/Depr | 52.25% | ||
| Cap/Sales | 4.44% | ||
| Interest Coverage | 14.25 | ||
| Cash Conversion | 51.74% | ||
| Profit Quality | 72.36% | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 2.57 |
F-Score6
WACC7.61%
ROIC/WACC1.29
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)14.82%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%37.78%
EPS Next Y7.64%
EPS Next 2Y11.63%
EPS Next 3Y11.7%
EPS Next 5YN/A
Revenue 1Y (TTM)3.96%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-3.7%
Revenue Next Year-3.57%
Revenue Next 2Y1.66%
Revenue Next 3Y4.48%
Revenue Next 5YN/A
EBIT growth 1Y15.63%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year34.87%
EBIT Next 3Y14.76%
EBIT Next 5YN/A
FCF growth 1Y5.09%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y-0.01%
OCF growth 3Y1.79%
OCF growth 5Y2.81%